1156.60
-9.16%
Deven Choksey
Tatva Chintan is transitioning into a stronger growth phase primarily driven by SDA recovery, clearer electrolyte-salt commercialization, scalable agro/pharma pipelines, and a structurally high-entry-barrier semiconductor opportunity.
Tatva Chintan Pharma Chem Ltd. is trading below its 30 day SMA of 1353.6
More from Tatva Chintan Pharma Chem Ltd.
Recommended